BMED saw its Moving Average Convergence Divergence Histogram (MACD) turn negative on November 13, 2026. This is a bearish signal that suggests the stock could decline going forward. Tickeron's A.I.dvisor looked at 46 instances where the indicator turned negative. In 36 of the 46 cases the stock moved lower in the days that followed. This puts the odds of a downward move at 78%.
The 10-day RSI Indicator for BMED moved out of overbought territory on November 05, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 35 similar instances where the indicator moved out of overbought territory. In 24 of the 35 cases, the stock moved lower in the following days. This puts the odds of a move lower at 69%.
The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In 49 of 66 cases where BMED's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are 74%.
The Momentum Indicator moved below the 0 level on November 12, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on BMED as a result. In 72 of 96 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 75%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where BMED declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 77%.
BMED broke above its upper Bollinger Band on November 04, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
Following a +3.57% 3-day Advance, the price is estimated to grow further. Considering data from situations where BMED advanced for three days, in 223 of 273 cases, the price rose further within the following month. The odds of a continued upward trend are 82%.
The Aroon Indicator entered an Uptrend today. In 216 of 281 cases where BMED Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 77%.
The 10-day moving average for GKOS crossed bullishly above the 50-day moving average on October 26, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 13 of 13 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 90%.
GKOS moved above its 50-day moving average on October 20, 2026 date and that indicates a change from a downward trend to an upward trend.
Following a +8.53% 3-day Advance, the price is estimated to grow further. Considering data from situations where GKOS advanced for three days, in 248 of 316 cases, the price rose further within the following month. The odds of a continued upward trend are 78%.
The Aroon Indicator entered an Uptrend today. In 252 of 314 cases where GKOS Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 80%.
The 10-day RSI Indicator for GKOS moved out of overbought territory on November 05, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 44 similar instances where the indicator moved out of overbought territory. In 34 of the 44 cases, the stock moved lower in the following days. This puts the odds of a move lower at 77%.
The Stochastic Oscillator demonstrated that the ticker has stayed in the overbought zone for 3 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where GKOS declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 67%.
GKOS broke above its upper Bollinger Band on October 29, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Tickeron Profit vs. Risk Rating rating for this company is 14 (best 1 - 100 worst), indicating low risk on high returns. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock better than average.
The Tickeron Price Growth Rating for this company is 34 (best 1 - 100 worst), indicating steady price growth. GKOS’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Seasonality Score of 50 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron Valuation Rating of 87 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (19.395) is normal, around the industry mean (4.142). P/E Ratio (-68.627) is within average values for comparable stocks, (3.291). Projected Growth (PEG Ratio) (12.570) is also within normal values, averaging (11.253). Dividend Yield (0.000) settles around the average of (0.011) among similar stocks. P/S Ratio (15.456) is also within normal values, averaging (40.124).
The Tickeron PE Growth Rating for this company is 88 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is 96 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
GKOS | ||
|---|---|---|
OUTLOOK RATING 1..100 | 50 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 87 Overvalued | |
PROFIT vs RISK RATING 1..100 | 14 | |
SMR RATING 1..100 | 96 | |
PRICE GROWTH RATING 1..100 | 34 | |
P/E GROWTH RATING 1..100 | 88 | |
SEASONALITY SCORE 1..100 | 50 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
| BMED | GKOS | |
|---|---|---|
| RSI ODDS (%) | 3 days ago 69% | 3 days ago 77% |
| Stochastic ODDS (%) | 3 days ago 74% | 3 days ago 70% |
| Momentum ODDS (%) | 3 days ago 75% | N/A |
| MACD ODDS (%) | 3 days ago 78% | N/A |
| TrendWeek ODDS (%) | 3 days ago 73% | 3 days ago 79% |
| TrendMonth ODDS (%) | 3 days ago 81% | 3 days ago 78% |
| Advances ODDS (%) | 7 days ago 82% | 7 days ago 78% |
| Declines ODDS (%) | 3 days ago 77% | 3 days ago 67% |
| BollingerBands ODDS (%) | 3 days ago 64% | 3 days ago 70% |
| Aroon ODDS (%) | 3 days ago 77% | 3 days ago 80% |
A.I.dvisor tells us that BMED and CRL have been poorly correlated (+16% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that BMED and CRL's prices will move in lockstep.
| Ticker / NAME | Correlation To BMED | 1D Price Change % | ||
|---|---|---|---|---|
| BMED | 100% | -0.34% | ||
| CRL - BMED | 16% Poorly correlated | -0.83% | ||
| BDX - BMED | 15% Poorly correlated | +1.08% | ||
| MCRB - BMED | 13% Poorly correlated | -0.71% | ||
| GKOS - BMED | 13% Poorly correlated | -0.13% | ||
| VRTX - BMED | 13% Poorly correlated | -0.74% | ||
More | ||||
A.I.dvisor indicates that over the last year, GKOS has been loosely correlated with ISRG. These tickers have moved in lockstep 51% of the time. This A.I.-generated data suggests there is some statistical probability that if GKOS jumps, then ISRG could also see price increases.
| Ticker / NAME | Correlation To GKOS | 1D Price Change % | ||
|---|---|---|---|---|
| GKOS | 100% | -0.13% | ||
| ISRG - GKOS | 51% Loosely correlated | +0.84% | ||
| NTRA - GKOS | 48% Loosely correlated | -1.19% | ||
| RDNT - GKOS | 48% Loosely correlated | +0.50% | ||
| TWST - GKOS | 46% Loosely correlated | -2.29% | ||
| ALGN - GKOS | 43% Loosely correlated | +0.81% | ||
More | ||||
| 1 Day | |||
|---|---|---|---|
| ETFs / NAME | Price $ | Chg $ | Chg % |
| GVAL | 36.36 | 0.24 | +0.65% |
| Cambria Global Value ETF (GVAL) | |||
| MVRL | 7.93 | 0.05 | +0.58% |
| ETRACS Monthly Pay 1.5x Leveraged Mortgage REIT ETN (MVRL) | |||
| SLYV | 106.15 | 0.18 | +0.17% |
| State Street SPDR S&P 600 Small Cap Value ETF (SLYV) | |||
| ZAUG | 27.90 | -0.04 | -0.14% |
| Innovator 1 Yr August (ZAUG) | |||
| FFLS | 23.00 | -0.09 | -0.40% |
| Future Fund Long/Short ETF (FFLS) | |||